Panacea Biotec subsidiary Hungary GMP certificate revoked over non-compliance

Regulatory & Legal View source PDF Explain this filing

PANACEABIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.6%Reaction day

₹378.00

prior close

₹372.70

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.0%-1.6% vs market

Pharmaceuticals peers, median of 157sector-0.5%-2.2% vs sector

On the reaction day the stock moved 1.6 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.7

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.6-1.0-1.6-0.5-2.2

Next day

-3.7-1.8-1.9-1.2-2.5

-2.1+0.8-2.9+0.6-2.7

-0.6+1.8-2.3+1.0-1.6

-6.9+1.2-8.1+0.9-7.8

-5.4+0.7-6.1+0.1-5.4

-8.2-1.5-6.7-1.4-6.8

15d

-11.3-2.5-8.9-2.9-8.5

-14.8-7.2-7.6-5.0-9.8

-14.8-8.9-5.9-7.3-7.5

-2.0+5.5-7.5+0.4-2.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Hungary regulator NCPHP revoked GMP certificates for subsidiary Panacea Biotec Pharma's Baddi facility after finding non-compliance with EU manufacturing standards following an inspection from Jan 26 to 31, 2026. EU market revenue is only about 0.32 percent of Panacea Biotec consolidated revenue in FY25. Officials found no risk to already released products. Company is implementing corrective actions and will request re-inspection at the earliest.

Likely market impact

Direct revenue impact is minimal given small EU exposure. Negative regulatory signal; remediation and re-inspection timeline remain key for investors.